ReviewInternational journal of nanomedicine2026
Biomimetic Polymer-Based Nanomaterials for Immune-Responsive Hepatocellular Carcinoma Therapy.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths because of its late diagnosis, tumor heterogeneity, compromised liver function, and the poor efficacy of conventional treatment strategies. Although immune checkpoint inhibitors and adoptive immune therapy have shown promising results in some patients, these therapies are also less effective overall due to many factors. Biomimetic polymer nanomaterials have recently been explored as novel tools to address these challenges by combining synthetic polymeric carriers with biologically inspired elements, including cell membrane modification, receptor-targeting ligands, and smart designs. This review focuses on the therapeutic potential of the biomimetic polymer-based nanomaterials for hepatocellular carcinoma by covering their liver immunological characteristics, design principles, various types, and immune-modulating mechanisms with preclinical evidence, challenges, limitations, and future perspectives. Studies show that these nanoplatforms enable sustained circulation, evade the immune system, selectively accumulate in tumors, and provide controlled release of immunotherapeutic agents. Biomimetic approaches promote antigen presentation, immune modulation, and immune cell infiltration into the tumor microenvironment. Preclinical evidence shows that nanomaterial-based cancer vaccine therapy, immune cell reprogramming, and combination therapies work in synergy with checkpoint inhibitors to overcome immunosuppression, activate T cells, and suppress tumor growth. Regardless of these promising outcomes, factors such as complexity in fabrication, batch preparation variability, scalability, and biosafety over a long period of time make it difficult to translate them into the clinical environment. There is a need to overcome these challenges by optimal design, standardized preparation, and biosafety evaluation for the clinical translation of biomimetic nanoplatforms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.